Following a steep decline in its Covid-related sales, Pfizer is implementing a clear multi-pronged strategy to reignite growth. The pharmaceutical giant is focusing on strategic acquisitions, a robust development pipeline, and stringent cost management. Investors are now assessing the viability of this recovery plan and identifying which near-term projects could deliver results.
Strategic Shifts and Analyst Confidence
At yesterday’s TD Cowen Health Care Conference, CEO Albert Bourla outlined the company’s priorities in the wake of the pandemic boom. A core element involves accelerating value creation from recent acquisitions, most notably oncology specialist Seagen, to deliberately bolster its cancer treatment portfolio.
The company also aims to expedite key research milestones. Several Phase 3 trials are scheduled, particularly in the obesity drug arena. While Bourla emphasized innovation, he acknowledged potential headwinds, including pricing pressures and evolving regulatory landscapes that could impact commercialization and margins in certain segments.
In a boost for its oncology focus, Pfizer and Astellas recently reported positive Phase 3 data. The combination therapy of PADCEV (enfortumab vedotin) and Keytruda (pembrolizumab) significantly reduced the risk of cancer recurrence, disease progression, or death in patients with muscle-invasive bladder cancer. Such outcomes are critical for investors, as they enhance the potential for new products to fill the revenue gap left by declining Covid sales.
The broader development pipeline contains 102 candidates, with 32 in late-stage Phase 3 trials as of early 2026. Pfizer also expressed optimism regarding its vaccine portfolio, including the prospect of launching a potential first-ever Lyme disease vaccine.
Should investors sell immediately? Or is it worth buying Pfizer?
Sentiment received a further lift from analysts, with Argus Research upgrading the stock from “Hold” to “Buy.”
Financial Discipline and Future Challenges
Financially, Pfizer continues to navigate the post-Covid normalization. Management highlighted ongoing cost-reduction efforts and noted that newly launched products have already contributed meaningful revenue in 2025. Plans are in place to expand commercial infrastructure while preparing for the period following the loss of exclusivity for key patents.
Bourla also addressed concerns regarding leadership at the U.S. Food and Drug Administration’s vaccine division—a factor with implications for pipeline planning and regulatory pathways. Despite these challenges, the company’s dividend remains a key attraction for many investors. A quarterly dividend of $0.43 per share has been declared for Q1 2026, marking the 349th consecutive quarterly payout.
In today’s trading, the stock was slightly weaker at €23.18. The coming months will serve as a key test of whether Pfizer can deliver further concrete pipeline progress, especially in its prioritized areas of oncology and obesity treatments.
Ad
Pfizer Stock: Buy or Sell?! New Pfizer Analysis from March 3 delivers the answer:
The latest Pfizer figures speak for themselves: Urgent action needed for Pfizer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 3.
Pfizer: Buy or sell? Read more here...
